Date
Tuesday 10, September 2019
Chairs
Thomas Huber (Novartis, Switzerland)
Stefan Weigand (Roche, Switzerland)
Renè Assenberg (Janssen Biologics, Netherlands)
Abstract:
Disruptive innovations are driving future biotherapeutics to become more personalized, cost-effective and efficacious. The biotherapeutics are shifting from classical monoclonal antibodies towards more complex modalities, such as engineered antibodies, multi-specific antibodies, cell and gene therapies. The 2019 biotherapeutics forum discusses technology trends and developments required to progress current and future drug modalities from concepts to the market.
Tuesday, 10 September 2019
10.00 – 16.30
10.00
Fusion Proteins: Design principles and consequences for manufacturing
Dr. Stefan Schmidt (Bioatrium Visp, CH)
10.30
Challenges in CMC development of bispecific antibodies
Dr. Christian Cimander (GenMab, Copenhagen, DK)
11.00
Break
11.30
Master Checkpoint Cbl-b Inhibition: Ambulatory siRNA-based Autologous Cell Therapy for Cancer
Dr. Anderson Gaweco (Apeiron, Vienna, AT)
12.00
Gene Therapy CMC
Dr. Diane Blumenthal (Spark Therapeutics, Phiadelphia, USA)
12.30
Lunch Break & Industry Symposia
14.00
Therapeutic Use of Genome Editing – A Vision for the Future
Dr. Lorenz Mayr (GE Healthcare, Little Chalfont, UK)
14.30
mRNA as a platform technology ideally suited for individualized therapeutics
Dr. Andreas Kuhn (BioNtech, Mainz, DE)
15.00
Break
15.30
CMC opportunities and challenges in bringing new, complex modalities to the patient
Eileen Brett (Janssen Pharmaceuticals, Phiadelphia, USA)
16.00
Co-expression of IgG-like bispecifics for efficient manufacturing
Dr. Michael Bardroff (Novartis, Basel, CH)
Room Samarkand